Breast Biopsy Devices Market Analysis

The market by product is categorized into breast biopsy guidance systems, needle-based breast biopsy guns, breast biopsy needles, breast biopsy forceps and other products. The needle-based breast biopsy guns segment is bifurcated into vacuum-assisted biopsy (VAB) devices, fine needle aspiration biopsy (FNAB) devices, and core needle biopsy (CNB) devices. This segment garnered USD 568 million revenue size in the year 2022 and is projected to have the fastest-growing CAGR in the forecast period.

• Their ease of use, accurate lesion targeting, and compatibility with imaging guidance contribute to widespread adoption. Furthermore, advances in needle design and technology bolster diagnostic accuracy, instilling confidence among healthcare professionals.
  

Based on technique, the breast biopsy devices market is segmented into image guided biopsy and liquid biopsy. The image guided biopsy segment is further bifurcated into MRI guided breast biopsy, ultrasound guided breast biopsy, mammography guided stereotactic biopsy and other image guided biopsies. This segment garnered USD 1.3 billion revenue size in the year 2022.

• Image-guided biopsy dominates due to its superior precision, offering real-time visualization through techniques such as ultrasound or stereotactic guidance. This precision enhances diagnostic outcomes, instilling confidence in healthcare professionals.
  
• Furthermore, the technique's minimally invasive nature reduces patient discomfort, ensuring quicker recovery and driving widespread adoption.
  

Based on end-use, the breast biopsy devices market is segmented into hospitals and ambulatory surgical centres. The hospitals segment garnered USD 1.1 billion revenue size in the year 2022.

• Hospitals dominates the segment, leveraging advanced infrastructure and skilled professionals to integrate sophisticated biopsy procedures seamlessly. Their possession of cutting-edge imaging technologies fosters widespread adoption. Moreover, patient trust in hospital-based diagnostic services contributes to a preference for breast biopsy procedures in these settings.
  

U.S. breast biopsy devices market accounted for USD 649 million revenue size in 2022.

• The U.S. has taken a commanding position in the industry, primarily due to its advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and proactive breast cancer awareness programs.
  
• Furthermore, the country's robust reimbursement framework accelerates device adoption. For instance, in 2023, the American Cancer Society estimates 297,790 new cases of invasive breast cancer in the U.S., with an anticipated 43,700 women succumbing to the disease.